(Reuters) - Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion ... help accelerate growth in J&J's drugs business after the company ...

Intel Corp., the once-dominant chipmaker struggling to revive its business and finances, plans to turn its venture capital arm into a separate fund with a new name. The chipmaker will continue to ...

Click to Subscribe to Get Our Free HollywoodLife Daily Newsletter to get the hottest celeb news. Articles Trending Now ...

J&J's $132 per-share offer implies 39% premium Deal could kick off spree of activity in sector in 2025 CEO says such large deals not common The deal would help accelerate growth in J&J's drugs ...

Johnson & Johnson said Monday it would buy Intra-Cellular Therapies in a deal worth $14.6 billion ... potentially opening up a substantial market. J&J is paying $132 a share in cash for its ...

SAN FRANCISCO—Johnson & Johnson (J&J) has agreed to acquire Intra-Cellular Therapies for approximately $14.6 billion, the companies said, in the largest biopharma merger-and-acquisition (M&A ...

HistoSonics Inc., a medical device company whose backers include Johnson & Johnson’s venture capital arm, is weighing a US initial public offering as soon as this year, according to people ...

Redmi's freshly global Note 14 series features a trio of Pros - 4G, 5G (review here), and Pro+ 5G - and a pair of non-Pros - the 4G (first encounter here) and this - the Redmi Note 14 5G.

We have the new Realme 14 Pro+ at the office so let's do an unboxing. The global unit ships without the 80W charger you get in China. The rest of the accessories are the same - you get a case ...